Enovis (NYSE:ENOV – Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided EPS guidance of 3.100-3.250 for the period, compared to the consensus EPS estimate of 3.160. The company issued revenue guidance of $2.2 billion-$2.2 billion, compared to the consensus revenue estimate of $2.2 billion.
Enovis Price Performance
Shares of NYSE ENOV opened at $42.08 on Wednesday. Enovis has a twelve month low of $38.27 and a twelve month high of $63.96. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The firm has a market capitalization of $2.39 billion, a P/E ratio of -19.22 and a beta of 1.94. The stock’s 50-day simple moving average is $44.96 and its two-hundred day simple moving average is $44.37.
Wall Street Analysts Forecast Growth
Separately, Needham & Company LLC reissued a “buy” rating and set a $65.00 price objective on shares of Enovis in a research note on Thursday, November 7th.
About Enovis
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
Featured Articles
- Five stocks we like better than Enovis
- What is the S&P 500 and How It is Distinct from Other Indexes
- Twilio, Braze: The Top 2 CEP Platforms to Own in 2025
- Consumer Discretionary Stocks Explained
- Tempus AI Is a Buy, If You Can Handle the Volatility
- How to Plot Fibonacci Price Inflection Levels
- Massive Buybacks: 3 Stocks Returning Big Cash to Shareholders
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
